Saturday 17 October 2026
Export PRTCY’s income statement to Excel — free account
PureTech Health PLC Sponsored ADR
PRTCY Healthcare Biotechnology
PureTech Health PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, down 3.50% from fiscal 2024.
14.56
0.34
−2.28%
Follow PRTCY
| Dec '19 | Jan '20 | Dec '20 | Jan '21 | Dec '21 | Jan '22 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 3 | — | 5 | 3 | 6 | 4 |
P/E ratio |
20.92 | 20.92 | 35.29 | 36.93 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | 27.77 | 25.21 | 1.90 | 35.57 | 3.40 | 1.97 | 1.47 | 0.83 |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
2.47 | 3.22 | 3.63 | 2.70 | 3.23 | 4.01 | 5.21 | 3.82 | 4.61 | 2.87 |
Beneish M-Score |
— | — | (1.78) | — | (0.92) | — | 0.33 | (1.43) | (1.75) | 1.48 |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
(5.96) | (5.96) | (10.99) | (10.99) | (15.97) | (15.97) | (10.25) | (10.38) | (12.10) | (9.10) |
EV/EBITDA |
0.84 | 0.84 | 0.98 | 0.98 | 1.81 | 1.81 | 1.02 | 0.92 | 1.08 | 0.81 |
EV/Operating CF |
0.74 | 0.74 | 0.75 | 0.75 | 1.13 | 1.13 | 0.68 | 0.71 | 0.94 | 0.79 |
EV/FCF |
0.74 | 0.74 | 0.75 | 0.75 | 1.06 | 1.06 | 0.66 | 0.71 | 0.95 | 0.79 |
Quick Ratio |
1.18 | 2.26 | 2.25 | 2.10 | 2.16 | 3.87 | 3.84 | 6.64 | 9.19 | 6.41 |
Current Ratio |
1.21 | 2.29 | 2.29 | 2.22 | 2.22 | 3.99 | 3.99 | 6.76 | 9.33 | 6.59 |
Net Debt/EBITDA |
1.26 | 0.00 | 3.45 | 1.72 | 3.26 | 1.51 | 1.77 | 2.32 | 2.86 | 3.03 |
Debt/Assets |
0.00% | 0.00% | 1.50% | 23.89% | 1.60% | 10.56% | 2.19% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.02 | 0.38 | 0.03 | 0.14 | 0.03 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.00 | 0.01 | 0.00 | 0.02 | 0.00 | 0.02 | 0.00 | 0.01 | 0.01 |
Operating CF/Net income |
(0.23) | (22.03) | (22.03) | 2.61 | 2.61 | 3.55 | 3.55 | 1.59 | (2.51) | 0.78 |
Capex/Depreciation |
(1.88) | 0.00 | (0.82) | 0.00 | (0.77) | 0.00 | (0.24) | 0.13 | 0.07 | 0.08 |
Interest Coverage |
— | 0.00 | — | 0.00 | — | 0.00 | — | (14.39) | (16.89) | (2.24) |
| 89.35% | 0.00% | 0.92% | 0.00% | (9.79%) | 0.00% | (8.90%) | (13.25%) | 12.36% | (30.76%) | |
| 59.74% | 0.00% | 0.62% | 0.00% | (6.26%) | 0.00% | (6.11%) | (9.54%) | 8.25% | (19.30%) | |
ROIC |
(17.34%) | 0.00% | (28.25%) | 0.00% | (79.30%) | 0.00% | (58.07%) | (69.70%) | (290.85%) | (363.08%) |
Return on Tangible Assets |
824.17% | 2.31% | 2.34% | (18.66%) | (20.02%) | (15.06%) | (16.13%) | (21.82%) | 15.20% | (41.58%) |
Average Days of Receivables |
86.61 | 85.51 | 91.16 | 172.71 | 170.09 | 535.04 | 522.49 | 1,547.91 | 115.06 | 636.93 |
Research and Development Expense of Revenue |
875.37% | 695.60% | 695.61% | 635.33% | 635.33% | 976.01% | 976.01% | 2,889.94% | 1,438.57% | 1,214.14% |
Selling, General and Administrative Expense of Revenue |
605.26% | 363.58% | 420.12% | 287.33% | 328.96% | 333.58% | 390.52% | 1,600.45% | 1,480.30% | 1,000.60% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
147.53% | 0.00% | 91.08% | 0.00% | 80.23% | 0.00% | 94.11% | 132.58% | 473.28% | 176.48% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
4.78% | 4.78% | 2.83% | 2.71% | (0.62%) | (0.62%) | (1.22%) | (0.86%) | (1.17%) | (1.29%) |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.03 | 0.04 | 0.04 | 0.06 | 0.61 | 0.06 | 0.55 | 0.12 | 0.19 | 0.19 |
Operating CF per Share |
(0.35) | (0.47) | (0.46) | (0.55) | (5.52) | (0.69) | (6.28) | (3.83) | (5.28) | (3.54) |
Capex per Share |
(0.04) | 0.00 | (0.02) | 0.00 | (0.20) | 0.00 | (0.08) | 0.02 | 0.01 | 0.01 |
Free Cash Flow per Share |
(0.39) | (0.47) | (0.48) | (0.55) | (5.72) | (0.69) | (6.36) | (3.81) | (5.27) | (3.52) |
Cash per Share |
0.57 | 1.37 | 1.41 | 1.65 | 16.78 | 1.39 | 12.29 | 11.84 | 14.88 | 11.99 |
Shareholders Equity per Share |
2.29 | 2.26 | 2.29 | 2.09 | 20.38 | 2.14 | 19.23 | 16.58 | 16.03 | 12.69 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.29 | 2.26 | 2.29 | 2.09 | 20.38 | 2.14 | 19.23 | 16.58 | 16.03 | 12.69 |
Free Cash Flow |
(110.69) | (135.26) | (137.25) | (157.65) | (163.90) | (196.15) | (180.97) | (105.30) | (134.12) | (84.87) |
Working Capital |
29.64 | 224.69 | 233.42 | 278.81 | 275.67 | 325.01 | 289.31 | 295.83 | 344.87 | 258.71 |
Capital Expenditures |
(12.54) | (5.57) | (5.42) | (5.64) | (5.63) | (2.39) | (2.18) | 0.62 | 0.24 | 0.26 |
Net Current Asset Value |
(121.93) | 74.98 | 77.89 | 141.54 | 139.95 | 259.66 | 231.14 | 111.46 | 191.55 | 75.98 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
1.28 | 0.00 | 0.46 | 0.00 | 0.32 | 0.00 | 0.14 | (0.19) | (0.05) | (0.06) |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.31 | 0.17 | 0.29 | 0.16 | 0.27 | 0.23 | 0.39 | 0.52 | 0.51 | 0.64 |
Cash ROIC |
(13.62%) | 0.00% | (12.80%) | (12.11%) | (15.18%) | (18.03%) | (19.82%) | (13.41%) | (17.05%) | (14.28%) |
Accounts Receivable Turnover |
5.25 | 0.00 | 4.47 | 0.00 | 3.15 | 0.00 | 1.03 | 0.18 | 0.62 | 0.97 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
1.87 | 2.58 | 2.63 | 5.57 | 5.52 | 16.61 | 15.23 | 18.24 | 7.82 | 4.83 |
Average Payables |
12.38 | 14.19 | 20.83 | 16.65 | 28.82 | 32.80 | 45.33 | 49.47 | 35.56 | 25.10 |
Average Assets |
704.96 | 947.06 | 965.59 | 973.38 | 968.00 | 867.68 | 824.33 | 698.31 | 648.30 | 568.67 |
Average Common Equity |
471.36 | 647.54 | 651.97 | 626.90 | 618.84 | 596.64 | 565.87 | 502.91 | 433.08 | 356.80 |
Columns are period end dates